2942-14-5

Usage

Uses

Used in Pharmaceutical Industry:
5-METHOXYBENZOTHIAZOLE is used as a reactant for the preparation of 3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-ylbutanamides. These compounds are potent dipeptidyl peptidase IV (DPP-IV) inhibitors, which play a crucial role in the treatment of type 2 diabetes and other metabolic disorders. By inhibiting DPP-IV, these compounds help regulate blood glucose levels and improve overall metabolic health.
Additionally, 5-METHOXYBENZOTHIAZOLE may be utilized in the synthesis of other bioactive molecules and pharmaceuticals due to its unique chemical structure and reactivity. Its potential applications in drug discovery and development could be vast, spanning various therapeutic areas and targeting different diseases and conditions.

Upstream product

• 939803-90-4 C₈H₆BrNOS 
• 54346-87-1 2-amino-5-methoxybenzothiazole 
• 14482-32-7 2-amino-4-methoxybenzenethiol 
• 122-51-0 orthoformic acid triethyl ester 
• 14371-81-4 4-Methoxy-2-nitro-benzenethiol 
• 536-90-3 m-Anisidine 
• 631-61-8 ammonium acetate 
• 153898-63-6 2-iodo-5-methoxyaniline 
• 67-68-5 dimethyl sulfoxide 
• 68-12-2 N,N-dimethyl-formamide 
• 124-38-9 carbon dioxide 
• 59607-71-5 2-nitro-4-methoxyphenyl thiocyanate 
• 96-96-8 4-methoxy-2-nitroaniline 
• 64-18-6 formic acid 

Downstream Products

• 7686-41-1 5-hydroxybenzothioazole 
• 1354030-50-4 5-(4-(4-(2,3-dichlorophenyl)piperidin-1-yl)butoxy)benzo[d]thiazole 
• 1354030-51-5 UNC₉₉₉₄ 
• 1354030-52-6 5-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)benzo[d]thiazole 
• 1354030-71-9 5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)benzo[d]thiazole 
• 1354030-27-5 5-(4-(4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)butoxy)benzo[d]thiazole 
• 1354030-29-7 5-(3-(4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)propoxy)benzo[d]thiazole 
• 156086-02-1 5-methoxy-2-(4-methoxyphenyl)-1,3-benzothiazole 
• 101078-50-6 5-methoxy-2-(4′-tolyl)benzo[d]thiazole 
• 1242320-83-7 2-(4-chlorophenyl)-5-methoxy-1,3-benzothiazole 
• 54346-87-1 2-amino-5-methoxybenzothiazole 
• 1418220-40-2 5-methoxy-2-((4-methoxybenzyl)thio)benzo[d]thiazole 
• 72546-11-3 2-Amino-4-methoxybenzenesulfonic acid 
• 50993-65-2 5-oxiranylmethoxy-benzothiazole 

Relevant academic research and scientific papers

Dual Photoredox/Cobaloxime Catalysis for Cross-Dehydrogenative α-Heteroarylation of Amines

We report a dual-catalytic platform for the cross-dehydrogenative-coupling between (benzo-)thiazoles and amines which combines low loadings of an iridium photoredox catalyst and a cobaloxime catalyst under blue light irradiation. This transformation occurs without stoichiometric oxidants, giving products in moderate to excellent yields. DFT calculations support the key role of Co(II) for rearomatization of the radical-addition intermediate to generate the product.

Design, synthesis and biological evaluation of benz-fused five-membered heterocyclic compounds as tubulin polymerization inhibitors with anticancer activities

A series of benz-fused five-membered heterocyclic compounds were designed and synthesized as novel tubulin inhibitors targeting the colchicine binding site. Among them, compound 4d displayed the highest antiproliferative activity against four cancer cell lines with an IC50 value of 4.9?μM in B16-F10 cells. Compound 4d effectively inhibited tubulin polymerization in vitro (IC50 of 13.1?μM). Further, 4d induced cell cycle arrest in G2/M phase. Finally, 4d inhibited the migration of cancer cells in a dose-dependent manner. In summary, these results suggest that compound 4d represents a new class of tubulin inhibitors deserving further investigation.

K2S as Sulfur Source and DMSO as Carbon Source for the Synthesis of 2-Unsubstituted Benzothiazoles

We describe a three-component reaction of o-iodoanilines with K2S and DMSO that provides 2-unsubstituted benzothiazoles in moderate to good isolated yields with good functional group tolerance. Electron-rich aromatic amines and o-phenylenediamines instead of o-iodoanilines provided 2-unsubstituted benzothiazoles and 2-unsubstituted benzimidazoles with and without K2S under similar conditions. Notably, DMSO plays three vital roles: carbon source, solvent, and oxidant.

Synthetic method of ammonium acetate-mediated benzothiazole compound

The invention discloses a synthetic method of an ammonium acetate-mediated benzothiazole compound . The synthetic method comprises the steps: adding an o-haloaniline derivative, potassium sulfide, dimethyl sulfoxide, a catalyst, an additive 1 and an additive 2 into a reaction tube, carrying out a stirring reaction at the temperature of 130-150 DEG C, cooling to room temperature after the reactionis finished, and separating and purifying the product to obtain the benzothiazole compound. The invention provides the synthetic method of the benzothiazole compound by taking K2S as a sulfur source,DMSO as a carbon source and an oxidizing agent, an o-haloaniline derivative as a substrate and an ammonium acetate mediated three-component one-pot method. The method has the advantages of fewer reaction steps, mild reaction conditions, good functional group tolerance and the like.

Method for synthesizing benzothiazole by microwave radiation of benzothioamide compound in aqueous phase

The invention discloses a method for synthesizing benzothiazole by microwave radiation of a benzothioamide compound in an aqueous phase. The method includes the steps: adding the benzothioamide compound into the aqueous phase under microwave conditions; performing cyclization under alkaline conditions to generate the benzothiazole. The method for preparing the benzothiazole is environmentally friendly, simple and convenient in operation, safe, cheap and efficient. Compared with the prior art, the method is applicable to a lot of functional groups, high in yield, few in by-products, simple in operation, safe, low in cost and environmentally friendly.

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

Atmospheric CO2 promoted synthesis of N-containing heterocycles over B(C6F5)3 catalyst

B(C6F5)3 combined with atmospheric CO2 was found to be highly effective for the cyclization of ortho-substituted aniline derivatives with N,N-dimethylformamide (DMF), and a series of N-containing heterocycles including benzothiazoles, benzimidazoles, quinazolinone and benzoxazole were obtained in good to excellent yields.

Ionic Liquid-Catalyzed C-S Bond Construction using CO2 as a C1 Building Block under Mild Conditions: A Metal-Free Route to Synthesis of Benzothiazoles

The construction of the C-S bond using CO2 as a C1 feedstock can be considered as a green route for the synthesis of S-containing compounds and is of great significance. Herein, we report the acetate-based ionic liquids (ILs)-catalyzed synthesis of benzothiazoles via cyclization of 2-aminothiophenols with CO2 and hydrosilane under mild conditions (e.g., 60 °C, 0.5 MPa). It was found that the IL (e.g., 1-butyl-3-methylimidazolium acetate, [Bmim][OAc]) served as a multifunctional catalyst with activating CO2 and hydrosilane to form a formoxysilane intermediate, as well as simultaneously activating 2-aminothiophenols through a hydrogen bond, finally resulting in the production of benzothiazoles. [Bmim][OAc] showed the best performance, and a series of benzothiazoles were obtained in high yields. To the best of our knowledge, this is the first protocol for the synthesis of benzothiazoles using CO2 as a C1 building block under metal-free and mild conditions.

FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS

The present invention relates to novel functionally selective ligands of dopamine D2 receptors, including agonists, antagonists, and inverse agonists. The invention further relates to the use of these compounds for treating central nervous system disorders related to D2 receptors.

Synthesis and evaluation of 2-pyridylbenzothiazole, 2-pyridylbenzoxazole and 2-pyridylbenzofuran derivatives as 11C-PET imaging agents for β-amyloid plaques

The syntheses and SAR of new series of β-amyloid binding agents are reported. The effort to optimize signal-to-background ratios for these ligands are described. Compounds 8, 21 and 30 displayed desirable lipophilicity and pharmacokinetic properties. Compounds 8 and 21 were evaluated with in vitro autoradiographic studies and in vivo in APP/PS1 transgenic mice. It is shown that it was possible to increase the signal-to-background ratios compared to PIB 1, as demonstrated by compounds 8 and 21.